Newsletter Tool

Today's Rundown

Roche's TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug
HCA, CHS execs 'hopeful' deferred care will trickle back to hospitals in 2022
Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet
Researchers uncover the brain's link to SIDS, setting up potential infant screening test
Trial for controversial China-made Alzheimer’s drug aborted as capital raise hits snag, COVID hurts sales
Crossover Health is opening health centers in new markets. Here's where the medical group is going next
Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicava
Medtronic makes FTC-mandated sale to close Intersect ENT deal and scores FDA nod to boot
Update: Checkmate details bleak future if $250M Regeneron merger does not close
BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal
Bristol Myers sells NY biologics plant for $160M to fuel Lotte's drugmaking ambitions
Field Trip, Nue Life team up to expand psychedelic treatment into the home
FDA clears BD's newest molecular diagnostics machine and its first test, a 3-in-one STI screener

Featured Story

Roche's TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug

By Nick Paul Taylor

That was fast. Just 39 hours after the bombshell failure of Roche’s TIGIT trial, iTeos Therapeutics revealed it and GlaxoSmithKline are assessing “how best to proceed with additional clinical development” of their rival asset in light of the phase 3 flop.

HCA, CHS execs 'hopeful' deferred care will trickle back to hospitals in 2022

By Dave Muoio

Promising volume recovery in the months following omicron's surge has hospital chains cautiously optimistic about short-term consumer demand and flat out bullish for the years to come.

Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet

By Angus Liu

Despite an ongoing strategic review, Novartis' generics engine keeps churning out new products. Sandoz has launched the first fully substitutable U.S. generic of Roche’s blockbuster idiopathic pulmonary fibrosis therapy Esbriet.

Researchers uncover the brain's link to SIDS, setting up potential infant screening test

By Conor Hale

“This discovery changes the narrative around SIDS," said lead researcher Carmel Harrington, who lost her own child to sudden infant death syndrome 29 years ago.

Trial for controversial China-made Alzheimer’s drug aborted as capital raise hits snag, COVID hurts sales

By Angus Liu

A clinical trial for an Alzheimer’s disease drug approved in China that would otherwise have supported a potential FDA submission has stopped.

Crossover Health is opening health centers in new markets. Here's where the medical group is going next

By Heather Landi

Crossover Health, a tech-enabled medical group, is expanding its national footprint of brick-and-mortar clinics and plans to open new health centers in Seattle and Austin. In an exclusive interview, Crossover's chief medical officer Stephen Ezeji-Okoye, M.D., shared with Fierce Healthcare how the company's model of care is different from other primary care players.

Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicava

By Kevin Dunleavy

The FDA has approved an oral version of Mitsubishi Tanabe’s ALS drug Radicava, which can be taken at home and, if necessary, through a feeding tube. Radicava was initially approved in the U.S. in 2017, becoming the first new treatment for the condition in 22 years.

Medtronic makes FTC-mandated sale to close Intersect ENT deal and scores FDA nod to boot

By Andrea Park

It may have taken an order from the FTC to get there, and Medtronic may be getting less bang for its buck than initially expected, but the medtech giant’s acquisition of Intersect ENT is finally complete.

Update: Checkmate details bleak future if $250M Regeneron merger does not close

By Annalee Armstrong

“Difficulties in employee retention.” “No assurance that we will be able to successfully raise sufficient additional capital.” “We may be forced to delay, reduce or eliminate some or all of our research and development programs.” This is the future facing Checkmate Pharmaceuticals if the $250 million Regeneron deal does not happen.

BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

By Annalee Armstrong

A day after getting a nice fat—and sorely needed—paycheck from Bristol Myers, BridgeBio has sold off a priority review voucher, adding $110 million to its coffers.

Bristol Myers sells NY biologics plant for $160M to fuel Lotte's drugmaking ambitions

By Fraiser Kansteiner

Under the deal, Lotte will continue to manufacture products for Bristol Myers from the plant as part of a “newly-established CDMO relationship” with the Big Pharma. Lotte is due to inherit the East Syracuse site’s operations and assets, including property, equipment and the plant’s workforce.

Field Trip, Nue Life team up to expand psychedelic treatment into the home

By Anastassia Gliadkovskaya

The companies hope their partnership to inspire more collaboration in the industry and improve the quality of the national conversation around psychedelics, which remain stigmatized.

FDA clears BD's newest molecular diagnostics machine and its first test, a 3-in-one STI screener

By Andrea Park

When it comes to molecular diagnostics, BD is betting that three heads are better than one.

Senior Editors: Ben Adams, Annalee Armstrong, Conor Hale, Heather Landi, Paige Minemyer, Eric Sagonowsky

Advertise | Contact

Editor in Chief: Tracy Staton

Managing Editor: Querida Anderson

Senior Multimedia Producer: Teresa Carey

Multimedia Producer: Caleb Hodgson

Publisher: Rebecca Willumson

Group Sales Director: Angelique Alcover

Manage Your Subscriptions

Trouble with your subscription?
Contact Support

This email was sent to newsletter@newslettercollector.com as part of the Fierce Life Sciences email list

PM Tracker